Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$691.1m

Capricor Therapeutics Valuation

Is CAPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$197.40
Fair Value
92.4% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: CAPR ($15.04) is trading below our estimate of fair value ($197.4)

Significantly Below Fair Value: CAPR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAPR?

Key metric: As CAPR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CAPR. This is calculated by dividing CAPR's market cap by their current revenue.
What is CAPR's PS Ratio?
PS Ratio29.4x
SalesUS$23.23m
Market CapUS$691.14m

Price to Sales Ratio vs Peers

How does CAPR's PS Ratio compare to its peers?

The above table shows the PS ratio for CAPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average25.4x
IMNM Immunome
68x52.7%US$656.0m
VERV Verve Therapeutics
26.4x-6.2%US$627.4m
TRDA Entrada Therapeutics
2.2x-58.2%US$473.4m
ARDX Ardelyx
5x21.1%US$1.3b
CAPR Capricor Therapeutics
29.4x44.2%US$691.1m

Price-To-Sales vs Peers: CAPR is expensive based on its Price-To-Sales Ratio (29.4x) compared to the peer average (25.4x).

Price to Sales Ratio vs Industry

How does CAPR's PS Ratio compare vs other companies in the US Biotechs Industry?

139 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.2x1.2%US$21.31b
MRNA Moderna
3x10.2%US$15.79b
INCY Incyte
3.5x5.4%US$14.21b
EXAS Exact Sciences
3.9x9.3%US$10.37b
CAPR 29.4xIndustry Avg. 9.9xNo. of Companies139PS01632486480+
139 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CAPR is expensive based on its Price-To-Sales Ratio (29.4x) compared to the US Biotechs industry average (9.9x).

Price to Sales Ratio vs Fair Ratio

What is CAPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAPR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29.4x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: CAPR is expensive based on its Price-To-Sales Ratio (29.4x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$15.04
US$41.29
+174.5%
37.9%US$77.00US$25.00n/a7
Jan ’26US$13.80
US$41.29
+199.2%
37.9%US$77.00US$25.00n/a7
Dec ’25US$19.01
US$41.29
+117.2%
37.9%US$77.00US$25.00n/a7
Nov ’25US$19.45
US$40.67
+109.1%
43.2%US$77.00US$25.00n/a6
Oct ’25US$15.01
US$34.40
+129.2%
22.6%US$43.00US$25.00n/a5
Sep ’25US$4.57
US$19.80
+333.3%
58.4%US$40.00US$8.00n/a5
Aug ’25US$3.91
US$19.80
+406.4%
58.4%US$40.00US$8.00n/a5
Jul ’25US$4.84
US$19.80
+309.1%
58.4%US$40.00US$8.00n/a5
Jun ’25US$5.68
US$19.80
+248.6%
58.4%US$40.00US$8.00n/a5
May ’25US$5.33
US$21.00
+294.0%
59.3%US$40.00US$8.00n/a4
Apr ’25US$7.10
US$21.00
+196.0%
59.3%US$40.00US$8.00n/a4
Mar ’25US$4.57
US$18.75
+310.7%
66.8%US$40.00US$8.00n/a4
Feb ’25US$4.07
US$18.75
+360.7%
66.8%US$40.00US$8.00US$15.044
Jan ’25US$4.89
US$22.33
+356.7%
56.2%US$40.00US$12.00US$13.803
Dec ’24US$2.96
US$22.33
+654.5%
56.2%US$40.00US$12.00US$19.013
Nov ’24US$2.80
US$22.33
+697.6%
56.2%US$40.00US$12.00US$19.453
Oct ’24US$3.42
US$15.00
+338.6%
16.3%US$18.00US$12.00US$15.013
Sep ’24US$6.61
US$15.00
+126.9%
16.3%US$18.00US$12.00US$4.573
Aug ’24US$4.59
US$15.00
+226.8%
16.3%US$18.00US$12.00US$3.913
Jul ’24US$4.78
US$15.00
+213.8%
16.3%US$18.00US$12.00US$4.843
Jun ’24US$4.55
US$15.00
+229.7%
16.3%US$18.00US$12.00US$5.683
May ’24US$3.91
US$15.00
+283.6%
16.3%US$18.00US$12.00US$5.333
Apr ’24US$4.22
US$15.00
+255.5%
16.3%US$18.00US$12.00US$7.103
Mar ’24US$5.03
US$15.00
+198.2%
16.3%US$18.00US$12.00US$4.573
Feb ’24US$4.23
US$15.00
+254.6%
16.3%US$18.00US$12.00US$4.073
Analyst Price Target
Consensus Narrative from 7 Analysts
US$41.29
Fair Value
63.6% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 22:50
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Capricor Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Reni BenjaminH.C. Wainwright & Co.
Joseph PantginisH.C. Wainwright & Co.